Home Healthcare Pharmaceuticals Narcolepsy Therapeutics Market

Narcolepsy Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy), By Product (Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Narcolepsy Therapeutics Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Narcolepsy with Cataplexy
    2. Narcolepsy without Cataplexy
    3. Secondary Narcolepsy
  2. Narcolepsy Therapeutics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Central Nervous System Stimulants
    2. Sodium Oxybate
    3. Selective Serotonin Reuptake Inhibitor
    4. Tricyclic Antidepressants
    5. Others
  3. Regional Narcolepsy Therapeutics Market
    1. North America
      1. North America Narcolepsy Therapeutics Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
      2. North America Narcolepsy Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Central Nervous System Stimulants
        2. Sodium Oxybate
        3. Selective Serotonin Reuptake Inhibitor
        4. Tricyclic Antidepressants
        5. Others
      3. U.S.
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      4. Canada
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
    2. Europe
      1. Europe Narcolepsy Therapeutics Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
      2. Europe Narcolepsy Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Central Nervous System Stimulants
        2. Sodium Oxybate
        3. Selective Serotonin Reuptake Inhibitor
        4. Tricyclic Antidepressants
        5. Others
      3. U.K.
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      4. Germany
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      5. France
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      6. Spain
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      7. Italy
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      8. Russia
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      9. Nordic
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      10. Benelux
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      11. Rest of Europe
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
    3. APAC
      1. APAC Narcolepsy Therapeutics Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
      2. APAC Narcolepsy Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Central Nervous System Stimulants
        2. Sodium Oxybate
        3. Selective Serotonin Reuptake Inhibitor
        4. Tricyclic Antidepressants
        5. Others
      3. China
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      4. Korea
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      5. Japan
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      6. India
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      7. Australia
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      8. Taiwan
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      9. South East Asia
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      10. Rest of Asia-Pacific
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
    4. Middle East and Africa
      1. Middle East and Africa Narcolepsy Therapeutics Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
      2. Middle East and Africa Narcolepsy Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Central Nervous System Stimulants
        2. Sodium Oxybate
        3. Selective Serotonin Reuptake Inhibitor
        4. Tricyclic Antidepressants
        5. Others
      3. UAE
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      4. Turkey
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      5. Saudi Arabia
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      6. South Africa
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      7. Egypt
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      8. Nigeria
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      9. Rest of MEA
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
    5. LATAM
      1. LATAM Narcolepsy Therapeutics Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
      2. LATAM Narcolepsy Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Central Nervous System Stimulants
        2. Sodium Oxybate
        3. Selective Serotonin Reuptake Inhibitor
        4. Tricyclic Antidepressants
        5. Others
      3. Brazil
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      4. Mexico
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      5. Argentina
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      6. Chile
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      7. Colombia
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
      8. Rest of LATAM
        1. Narcolepsy with Cataplexy
        2. Narcolepsy without Cataplexy
        3. Secondary Narcolepsy
        4. Central Nervous System Stimulants
        5. Sodium Oxybate
        6. Selective Serotonin Reuptake Inhibitor
        7. Tricyclic Antidepressants
        8. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.